...
首页> 外文期刊>癌と化学療法 >Translational research on lung cancer--EGFR gene mutation
【24h】

Translational research on lung cancer--EGFR gene mutation

机译:肺癌翻译研究 - EGFR基因突变

获取原文
获取原文并翻译 | 示例
           

摘要

Recent reports that activating mutations of the EGFR have a significant association with the response to gefitinib drew much attention. Mutations are more frequently observed in Oriental patients, females, non-smokers and adenocarcinoma patients, which correspond to patient profiles predictive of a good clinical response with gefitinib. In vitro experiments also revealed EGFR mutant cell lines are highly sensitive to gefitinib. It seems that development of tailor-made therapy of lung cancer would be possible by the test for EGFR gene mutations. Furthermore, EGFR mutations are the first molecular change known to specifically occur in lung cancer, preferentially in never smokers, especially in adenocarcinoma that is increasing in incidence. It is ultimately necessary to identify non-tobacco-related carcinogens that cause EGFR mutations for effective prevention of lung cancer.
机译:最近的报道称,激活EGFR的突变与对Gefitinib的反应有重大关联,这提高了很多关注。 在东方患者,女性,非吸烟者和腺癌患者中更常见的突变,其对应于患者谱预测与吉非替尼的良好临床反应。 体外实验还揭示了EGFR突变体细胞系对吉替尼高度敏感。 似乎通过测试EGFR基因突变的测试,可以进行量身定制的肺癌治疗的发展。 此外,EGFR突变是已知在肺癌中特异性发生的第一种分子变化,优先在从不吸烟者,特别是在发病率增加的腺癌中。 最终需要识别非烟草相关的致癌物,导致EGFR突变以有效预防肺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号